Hint mode is switched on Switch off
For swift navigation between sections

GridAI Technologies
LEI 549300I3YKRXWGWPG039

PDF download

Choose all Reset all
Download Cancel
Organization name
GridAI Technologies Corp.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Awards

News

14/05/2026 GridAI Technologies: Entry Into A Material Definitive Agreement, Financial Statements And Exhibits
04/05/2026 GridAI Technologies: Other Events
22/04/2026 GridAI Technologies: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Regulation Fd Disclosure, Financial Statements And Exhibits
01/04/2026 GridAI Technologies: Triggering Events That Accelerate Or Increase A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement
31/12/2025 GridAI Technologies: Completion Of Acquisition Or Disposition Of Assets, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300I3YKRXWGWPG039
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001604191
  • EIN
    46-4993860
Registration is required to get access.